To test this hypothesis, we probed the activity of BET/MEK inhibitor combinations in cancer cell lines with and without RAS pathway mutations (mutations in RAS, BRAF, or NF1), and with varying levels of sensitivity to GSK525762. The gene discussed is BRAF; the disease is cancer.